

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 3, 2009

NEOSTEM, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

0-10909
(Commission
File Number)

22-2343568
(IRS Employer
Identification No.)

420 Lexington Avenue, Suite 450, New York, New York 10170
(Address of Principal Executive Offices)(Zip Code)

(212) 584-4180
Registrant's Telephone Number

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

NEOSTEM, INC. ("NEOSTEM" OR THE "COMPANY") FILED A REGISTRATION STATEMENT WITH THE SECURITIES AND EXCHANGE COMMISSION ("SEC") THAT CONTAINS A PRELIMINARY JOINT PROXY STATEMENT/PROSPECTUS, IN CONNECTION WITH THE PROPOSED MERGER (THE "MERGER") OF CHINA BIOPHARMACEUTICALS HOLDINGS, INC. ("CBH") WITH AND INTO CBH ACQUISITION LLC, A WHOLLY OWNED SUBSIDIARY OF NEOSTEM, AND RELATED TRANSACTIONS, AS DESCRIBED IN THE REPORTS ON THE FORMS 8-K FILED WITH THE SEC ON NOVEMBER 6, 2008, JULY 8, 2009, AND SEPTEMBER 2, 2009, AND THE EXHIBITS THERETO. SECURITYHOLDERS OF NEOSTEM AND OTHER INTERESTED PERSONS ARE ADVISED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS IN CONNECTION WITH NEOSTEM'S SOLICITATION OF PROXIES FOR THE SPECIAL MEETING BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION. SUCH PERSONS CAN ALSO READ NEOSTEM'S PROXY STATEMENT FOR ITS 2009 ANNUAL MEETING OF STOCKHOLDERS FILED WITH THE SEC ON APRIL 14, 2009 AND SUBSEQUENT FORMS 8-K FOR INFORMATION ABOUT THE DIRECTORS, EXECUTIVE OFFICERS, AND PRINCIPAL STOCKHOLDERS OF NEOSTEM. THE FINAL PROXY STATEMENT/PROSPECTUS WILL BE SENT TO STOCKHOLDERS OF NEOSTEM SEEKING THEIR APPROVAL OF THE PROPOSED MERGER AND OTHER MATTERS. INVESTORS AND SECURITY HOLDERS WILL BE ABLE TO OBTAIN THE DOCUMENTS FREE OF CHARGE AT THE SEC'S WEBSITE, [HTTP://WWW.SEC.GOV](http://www.sec.gov). SINCE SUCH FINAL DOCUMENTS ARE NOT CURRENTLY AVAILABLE, NEOSTEM'S STOCKHOLDERS WILL RECEIVE INFORMATION AT AN APPROPRIATE TIME AS TO HOW TO OBTAIN TRANSACTION-RELATED DOCUMENTS FREE OF CHARGE FROM NEOSTEM.

NEOSTEM, CBH AND THEIR RESPECTIVE DIRECTORS, EXECUTIVE OFFICERS, AFFILIATES AND OTHER PERSONS MAY BE DEEMED TO BE PARTICIPANTS IN THE SOLICITATION OF PROXIES FOR THE SPECIAL MEETING OF NEOSTEM STOCKHOLDERS TO BE HELD TO APPROVE THE MERGER AND OTHER MATTERS. ADDITIONAL INFORMATION REGARDING THE INTERESTS OF POTENTIAL PARTICIPANTS IS INCLUDED IN THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER MATERIALS FILED BY NEOSTEM WITH THE SEC.

THIS COMMUNICATION SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY SECURITIES, NOR SHALL THERE BE ANY SALE OF SECURITIES IN ANY JURISDICTIONS IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION. NO OFFERING OF SECURITIES SHALL BE MADE EXCEPT BY MEANS OF A PROSPECTUS MEETING THE REQUIREMENTS OF SECTION 10 OF THE SECURITIES ACT OF 1933, AS AMENDED.

Safe Harbor for Forward-Looking Statements

General

This Current Report on Form 8-K, the exhibit hereto and the documents referred to herein contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. When used in this Current Report, statements that are not statements of current or historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "plan," "intend," "may," "will," "expect," "believe," "could," "anticipate," "estimate," or "continue" or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements. Additionally, statements concerning our ability to successfully develop the adult stem cell business at home and abroad, the future of regenerative medicine and the role of adult stem cells in that future, the future use of adult stem cells as a treatment option and the role of VSELs in that future, and the potential revenue growth of such business are forward-looking statements. Our future operating results are dependent upon many factors, and the Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control. Forward-looking statements may not be realized due to a variety of factors, including, without limitation, (i) the Company's ability to manage the business despite continuing operating losses and cash outflows; (ii) the Company's ability to obtain sufficient capital or a strategic business arrangement to fund its operations and expansion plans, including meeting its financial obligations under various licensing and other strategic arrangements and the successful commercialization of the relevant technology; (iii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of the business; (iv) competitive factors and developments beyond the Company's control; (v) scientific and medical developments beyond the Company's control; (vi) the Company's inability to obtain appropriate governmental licenses or any other adverse effect or limitations caused by government regulation of the business; (vii) whether any of the Company's current or future patent applications result in issued patents and the Company's ability to obtain and maintain other rights to technology required or desirable for the conduct of its business; (viii) whether any potential strategic benefits of various licensing transactions will be realized and whether any potential benefits from the acquisition of these new licensed technologies will be realized; (ix) whether the Company can obtain the consents it may require to sublicense arrangements from technology licensors in connection with technology development; (x) the Company's ability to maintain its NYSE Amex listing or to obtain another exchange listing; and (xi) the other factors discussed in Item 1A, "Risk Factors" contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 (the "Form 10-K") and in other reports that we file with the SEC.

Proposed Merger; Independent China Expansion Activities

Additional risks and uncertainties relate to (i) the Company's proposed Merger with CBH to acquire a 51% ownership interest in Suzhou Erye Pharmaceuticals Company Ltd., a Sino-foreign joint venture with limited liability organized under the laws of the People's Republic of China; and (ii) the Company's other expansion activities in China, that may cause actual future experience and results to differ materially from those discussed in these forward-looking statements. Important factors (i) related to the proposed Merger that might cause such a difference include, but are not limited to, (a) costs related to the Merger; (b) failure of the Company's or CBH's stockholders to approve the Merger; (c) the Company's or CBH's inability to satisfy the conditions of the Merger; including obtaining the necessary approvals from the PRC governmental authorities (d) the Company's inability to maintain its NYSE Amex listing or to obtain another exchange listing; (e) the inability to integrate the Company's and CBH's businesses successfully and grow such merged businesses as anticipated; (f) the need for outside financing to meet capital requirements; and (g) failure to have an effective Joint Venture Agreement satisfactory to the parties and regulatory authorities; (ii) related to the Company's independent expansion activities in China that might cause such a difference include, but are not limited to, (a) costs related to funding these initiatives; (b) the successful application under Chinese law of the variable interest entity structure to the Company's business, which structure the Company is relying on to conduct its business in China due to the fact that the Catalogue Guiding Foreign Investment in Industries in China categorizes the stem cell business as a prohibited business in China; (c) the inability to integrate the Company and the business operations in China successfully and grow such merged businesses as anticipated; and (d) the need for outside financing to meet capital requirements; and (iii) related to each of the Merger and the Company's other expansion activities in China, respectively, the other events and factors disclosed in the Company's Current Reports on Form 8-K dated November 2, 2008 and July 2, 2009, respectively, relating to the Merger and expansion into China, respectively, and other risk factors discussed in Item 1A, "Risk Factors" contained in the Company's Form 10-K and in other periodic Company filings with the SEC and disclosed in the Proxy Statement/Registration Statement on Form S-4 filed with the SEC in connection with the Merger. The Company's filings with the Securities and Exchange Commission are available for review at www.sec.gov under "Search for Company Filings." Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Item 1.01. Entry into a Material Definitive Agreement.

NeoStem, Inc. has entered into an agreement for the lease of space from Rivertech Associates II, LLC, c/o The Abbey Group (the "Landlord") at 840 Memorial Drive, Cambridge, Massachusetts with a lease term effective September 1, 2009 through August 31, 2012 (the "Lease"). The space will be used for general office, research and development, and laboratory space (inclusive of an adult stem cell collection center). The base rent under the Lease is \$567,700 for the first year, \$356,840 for the second year and \$369,005 for the third year. In addition, the Company will be responsible for certain costs and charges specified in the Lease, including utilities, operating expenses and real estate taxes. The security deposit is \$84,141, which may be reduced to \$56,094 if Company has not defaulted in the performance of its obligations under the lease prior to the second lease year. To help defray the cost of the Lease, Company will share with Alnara Pharmaceutical Inc. ("AP") certain of the leased premises and AP will pay the Company \$5,000 a month.

Item 7.01. Regulation FD Disclosure.

The Company is furnishing herewith the powerpoint presentation included as Exhibit 99.1 hereto.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit 99.1 Powerpoint Presentation dated September 9, 2009

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, NeoStem has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

NEOSTEM, INC.

By: /s/ Catherine M. Vaczy

Name: Catherine M. Vaczy

Title: Vice President and General Counsel

Date: September 9, 2009

NeoStem®



Robin Smith, MD, MBA
Chairman & CEO

Rodman & Renshaw
September 9, 2009

(NYSE AMEX: NBS)

Forward Looking Statements

Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include statements relating to NeoStem, Inc. (the "Company") in general as well as with respect to the Company's proposed merger (the "Merger") with China Biopharmaceuticals Holdings, Inc. ("CBH") and proposed share exchange (the "Share Exchange") whereby the Company would acquire a Hong Kong corporation whose wholly owned subsidiary is entitled to certain benefits from the business, personnel and finance of Shandong New Medicine Research Institute of Integrated and Traditional Western Medicine LLC ("Shandong"), and commencement of independent initiatives in China which may be in lieu of closing on the Share Exchange Agreement with Shandong.

General

Forward looking statements in this presentation include statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business, to develop the VSEL technology, the future of regenerative medicine and the role of adult stem cells and VSELs in that future, the future use of adult stem cells and VSELs as a treatment option and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena, its success in such arena and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to manage the business despite continuing operating losses and cash outflows; (ii) the Company's ability to obtain sufficient capital or a strategic business arrangement to fund its operations and expansion plans, including meeting its obligations under various licensing arrangements and the successful commercialization of its technology; (iii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of the business; (iv) competitive factors and developments beyond the Company's control; (v) scientific and medical developments beyond the Company's control; (vi) the Company's inability to obtain appropriate governmental licenses or any other adverse effect or limitations caused by government regulation of the business; (vii) whether any of the Company's current or future patent applications result in issued patents; (viii) whether any potential strategic benefits of various licensing transactions will be realized (ix) the Company's ability to maintain its NYSE AMEX listing; and (x) the other factors listed under "Risk Factors" in our annual report on Form 10-K for the year ended December 31, 2008 filed with the Securities and Exchange Commission ("SEC"); and (vi) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at www.sec.gov under "Search for Company Filings".

Proposed Merger; Independent China Expansion Activities

Additional risks and uncertainties relate to the proposed Merger and the Company's other expansion activities in China that may cause actual future experience and results to differ materially from those discussed in these forward-looking statements. Important factors (i) related to the proposed Merger that might cause such a difference include, but are not limited to, costs related to the Merger; failure of the Company's or CBH's stockholders to approve the Merger; the Company's or CBH's inability to satisfy the conditions of the Merger, including obtaining necessary approvals from the PRC governmental authorities; the Company's inability to maintain its NYSE AMEX listing; the inability to integrate the Company's and CBH's businesses successfully and grow such merged businesses as anticipated and described in this presentation; the need for outside financing to meet capital requirements; failure to have an effective Joint Venture Agreement satisfactory to the parties and regulatory authorities; (ii) related to the Company's independent expansion activities in China that might cause such a difference include, but are not limited to, costs related to funding these initiatives; the successful application of the variable interest entity to a prohibited business in China; the inability to integrate the Company and the business operations in China successfully and grow such merged businesses as anticipated and described in this presentation; and the need for outside financing to meet capital requirements; and (iii) related to each of the Merger, the expansion activities and the Company's other expansion activities in China, respectively, the other events and factors disclosed in the Company's Form 10-K for the year ended December 31, 2008 and other reports as filed with the SEC.



NeoStem Summary

- **Listed on the NYSE AMEX (ticker: NBS)**
- **Have completed approximately \$32 Million in financing through June 2009**
- **Leading operator of commercial autologous adult stem cell bank**
 - Pioneering pre-disease collection, processing and long-term storage of stem cells from adult donors for their own future medical treatment
 - Growing Network in major metropolitan areas in the U.S., providing geographical coverage of target customers spanning from California to NY
 - Expand Stem Cell Collection Center Network into Montclair, New Jersey and Malibu, California
 - Safe and convenient storage locations
 - Proprietary processes, infrastructure, methods and systems
 - Minimally invasive extraction procedure (“apheresis”)
 - Collaborate with Progenitor Cell Therapy to ensure cell processing is at the highest standard of cGMP



NeoStem Summary (continued)

- **Shift toward development therapeutics**
 - Worldwide exclusive license from and continuing collaboration with University of Louisville on VSEL Technology (VSEL very small embryonic like stem cells, found in individuals, may contain many physical characteristics typically found in embryonic stem cells)
 - Worldwide Licenses for Innovative Stem Cell Technology and Applications to Heal Chronic wounds
 - Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies
 - Exclusive license to develop orthopedic based therapies in Asia
- **Expansion into China**
 - Generate traditional therapies in the form of injectable pharmaceuticals
 - Accelerate Stem Cell Therapy
 - Collaborate with PRC experts to accelerate research development activity with licensed technology
 - Medical tourism due to advanced stem cell therapies developing at a faster pace outside the U.S.



Current Revenue Model

- Collection center fees
- Collection and processing fees from patients
- Storage fees (recurring revenue)
- Usage Fees
- Licensing of our technologies abroad



Growth Drivers for the Collection Business

	<p>Heart Disease <i>"It saved my life... my own stem cells."</i> BERNIE Adult Stem Cell Heart Recipient</p>		<p>Diabetes <i>"13 out of 14 kids are now off insulin.."</i> DR. RICHARD BURT Adult Stem Cell Transplanter, Northwestern Hospital</p>
	<p>Lupus <i>"My Lupus has been in remission for more than 5 years.."</i> KATHY Adult Stem Cell Recipient</p>		<p>Scleroderma <i>"I regained my life again... no more pain"</i> BRAD Adult Stem Cell Recipient</p>
	<p>Multiple Sclerosis <i>"Stem Cells helped me walk again.."</i> JANICE Adult Stem Cell Recipient</p>		




Future Stem Cell Therapies

Over 2,000 Adult Stem Cell Clinical Trials

- By 2017 it's forecasted that a minimum of 16 stem cells products will be approved through the FDA and used in 1.9 million annual procedures.*

- Autoimmune
- Diabetes/Metabolic
- Cardiovascular
- Orthopedic



Non-Closing Fracture

2 Months Post
BMSC
Fully Healed



- Worldwide projected to be a US \$20 billion business within 3 yrs.

*Source: Robert Young, RRY Publications, February 2008



NeoStem's Accessing Therapeutic Marketplace Through Licensing Arrangements

Wound Care:

- Vincent Falanga
 - Composition and Methods Using Stem Cells in Cutaneous Wound Healing

Skin Rejuvenation:

- Vincent Giampapa
 - Method and Composition for Restoration of Age-Related Tissue Loss in the Face or Selected Areas of the Body

Musculoskeletal:



- Regenexx; Christopher Centeno
 - Mesenchymal Stem Cell Isolation and Transplantation Method and System to be Used in a Clinical Setting (Orthopedic Uses)
 - Methods and Compositions for the Optimized Expansion and Implantation of Mesenchymal Stem Cells
 - Compositions and Methods for Cartilage Intervertebral Disc Repair
 - Compositions to Promote Implantation and Engraftment of Stem Cells

- **Very Small Embryonic Like (VSEL)** Stem Cell Technology exclusively licensed from the University of Louisville in November 2007:
 - Identification, isolation, and use of population of stem cells isolated from bone marrow, umbilical cord blood, and/or other sources and that are referred to as Very Small Embryonic-Like (VSEL) stem cells
 - Therapeutic treatment of various diseases with VSELS, including myocardial infarction, ischemic injury and stroke

*Each application above is a pending patent application in the US and those relating to VSELS are also pending abroad.

Very-Small Embryonic-like Stem Cells (VSELs)

NeoStem's research and development activities are focused on the proprietary **VSEL technology** with a view towards the development of future stem cell therapies for blood disorders, wound repair, musculoskeletal disease, anti-aging and other regenerative medicine applications.



Leukemia (2006), 1-7

Morphological and molecular characterization of novel population of CXCR4⁺ SSEA-4⁺ Oct-4⁺ very small embryonic-like cells purified from human cord blood – preliminary report


M Kucia¹, M Halasa², M Wysoczynski¹, M Baskiewicz-Masiuk², S Moldenhawer¹, E Zuba-Surma¹, R Czajka², W Wojakowski¹, B Machalinski² and MZ Ratajczak¹



NeoStem Stem Cells Collection Process

Each of us has a population of very primitive embryonic like stem cells that have remained in our bodies since birth

- Can be mobilized in the blood using NeoStem Process
- Should be easily recovered
- Cryopreserved
- Used for future therapeutic applications.



NeoStem®




Next Steps



CBH Acquisition

Proposed Combined Company



CBH's Pharma revenues and earnings provide certain stability that should be able to underpin the stem cell rollout

NBS brings innovative stem cell technology as well as credibility and domain knowledge which will be a platform for expansion into China



Why Is China Bio Acquisition So Significant

- China's annual drug bill is \$73 billion, 45% of total health care expenditures, which is double that of the international average.
- China's Health care reform projected to increase the national pharmaceutical market by annual growth rate of 22%, from \$24.5 billion currently to \$78 billion to 2013.
- China will move up to 3rd leading drugs market (behind US and Japan), up from 5th.

*Source: www.pharmatimes.com/WorldNews



Suzhou Erye Pharmaceutical

NBS signed agreement to acquire 51% ownership in Suzhou Erye Pharmaceutical Company in November 2008**. Form S-4 Registration Statement filed in July 2009. Anticipated Close before end of 2009.

**Historically
Consistent
increase in
Pharma revenues
and earnings**

- Provides a stronger balance sheet and P+L
- Established and profitable traditional Pharma business located in Suzhou, Jiangsu Province
- R&D, production and sales of pharmaceutical products as well as intermediate products
- 108 products generating US\$49.8 million* in revenues and net profit of US\$8.0 million* in 2008, which will initially be used for plant relocation and capacity expansion
- Relocation plan for existing plant will offer opportunity to improve manufacturing standards to World Health Organization ("WHO") levels from cGMP, as well as increase capacity
- Retention of cGMP and adoption of WHO standards should allow future potential in-licensing revenues and export of existing product line
- US will assist in enhancing pipeline of major products, including new drugs ready for commercialization in China



Competitive Landscape China

Other China Pharma Companies trade at Avg. 86.6x Current P/E

Comps Analysis – CBH

Name	Exchange	Country	Industry	Share Price (USD)	Mkt Cap (USD)	EPS 2008	P/E	
							Current	2008
Minsheng Investment Management Co., Inc.	China	China	Pharmaceuticals	\$1.04	\$551.70	(\$0.03)	68.80x	NA
S&P Pharmaceutical Industry	China	China	Pharmaceuticals	\$2.34	\$280.97	(\$0.07)	22.24x	NA
North China Pharmaceutical	China	China	Pharmaceuticals	\$1.22	\$1,257.06	\$0.06	32.65x	20.88x
Zhejiang Zhenyuan	China	China	Pharmaceuticals	\$1.15	\$144.15	\$0.01	72.79x	80.20x
Northeast Pharmaceutical Group	China	China	Pharmaceuticals	\$3.02	\$1,052.71	\$0.17	13.89x	17.78x
Jilin Pharmaceutical	China	China	Pharmaceuticals	\$1.27	\$201.95	\$0.03	322.50x	43.55x
Shanghai Pharmaceutical	China	China	Pharmaceuticals	\$1.68	\$958.53	\$0.02	73.35x	79.93x

Max	322.50x	80.20x
Min	13.89x	17.78x
Average	86.60x	48.47x
Median	68.80x	43.55x

*Note: Consolidated numbers reflect 100% revenue recognition, 51% NPAT recognition for Erye.

**Closing is subject to shareholder approval of the Company and China Biopharmaceuticals Holdings and the customary closing conditions.



Stem Cell Initiatives in PRC

- Partnership with leading hospitals and PRC governmental agencies
 - Translational R&D (Beijing Laboratory)
 - R&D grant
 - Clinical trials for selected indications
 - Commercial roll out of selected therapies (orthopedic, anti-aging cosmetic)
- Initial offices established in Beijing and Qingdao, with core team in place.
- Strategic alliance with major principal with respect to five provinces (Anhui, Fujian, Jiangsu, Jiangxi, and Zhejiang), the municipality of Shanghai, and Taiwan on revenue sharing basis with no capital outlay requirement by NBS.
- Targeting launch of revenue generating businesses by year end 2009.



Current Capitalization

	<u>August 18, 2009</u>	
	# of Shares	
Preferred stock; (authorized 5,000,000 shares)		
Series B convertible preferred stock (authorized 825,000 shares)		10,000
Series D convertible preferred stock (authorized 1,293,251 shares*)		1,293,251
Common stock (authorized 500,000,000 shares)		8,538,848
	Average Exercise Price	
Warrants Outstanding	\$ 2.81	18,225,533
Stock Options Outstanding	\$ 2.67	4,323,300

*Upon shareholder approval the Series D convertible preferred will be converted into 12,800,000 common shares



Post Merger Capitalization

Series C convertible preferred stock (authorized 8,177,512 shares)		8,177,512
Common stock (authorized 500,000,000 shares)		36,402,863
	Average Exercise Price*	
Warrants Outstanding	\$ 2.80	18,196,780
Series E Warrants	\$ 6.55	1,607,945
US Stock Options Outstanding	\$ 2.35*	6,438,300 **
Non US Stock Options Outstanding	\$ 1.70*	1,350,000

*Does not reflect proposed repricing of certain options and warrants that is subject to shareholder approval which is being sought at the same time as approval of the Merger

**Estimate based upon the closing price of NBS common stock on August 25, 2009 for options to be issued upon approval of the Merger.

***Estimate based on maximum number that could be outstanding post merger



Current Advisory Board Members

- **Wayne A. Marasco, M.D., Ph.D. Chairman** - Chairman of Scientific Advisory Board. Associate Professor-Department of Cancer and Immunology & AIDS at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. He is taking the lead in expanding the Company's academic relationships and research collaborations.
- **Douglas W. Losordo, MD** - For many years a Professor of Medicine at Tufts University School of Medicine and Chief of Cardiovascular Research at St. Elizabeth's Medical Center in Boston, Dr. Losordo was recently appointed Professor of Medicine at Northwestern University and Director of the Feinberg Cardiovascular Research Institute and Program in Cardiovascular Regenerative Medicine. A Fellow or Member of many national professional organizations, he currently serves on committees of the American College of Cardiology, the American Diabetes Association and the American Society of Gene Therapy where he chairs the Cardiovascular Gene Therapy Committee. Dr. Losordo serves as Principal Investigator in many grant research projects and has published widely, contributing to more than 300 professional articles, abstracts and book chapters in recent years. He also serves on the Editorial Boards of numerous medical specialty journals including *Stem Cells*, *Vascular Medicine and Circulation Research*.
- **Ron Rothenberg MD, FACEP** - Dr. Rothenberg is a Fellow of the American College of Emergency Physicians (FACEP) and is the founder of the California HealthSpan Institute in Encinitas, California. He was the 10th M.D. in the world to become fully board certified by the American Board of Anti-Aging Medicine. A graduate of Columbia University, College of Physicians and Surgeons, and a specialist in Emergency Medicine at Los Angeles County-USC Medical Center, he has served as Clinical Professor of Preventive and Family Medicine at the UCSD School of Medicine Clinical Facility. He is currently Attending Physician at Scripps Memorial Hospital in Encinitas.
- **Richard Gatti, MD** - Dr. Richard Gatti, a professor at the University of California, Los Angeles (UCLA) and renowned Pathologist at the UCLA Medical Center, was one of the early pioneers of bone marrow transplantation, among the earliest known forms of adult stem cell therapeutics, for immunodeficiency in the late sixties. Dr. Gatti is also a leading authority in the field of gene therapeutics and has authored or co-authored hundreds of papers related to the molecular identification and treatment of genetic disorders. He has worked for many years to help find a cure for Ataxia-Telangiectasia, a progressive neurological disorder of childhood, associated with increased cancer risk, immunodeficiency, radio sensitivity, and cell cycle defects.



Current Advisory Board Members (Contd.)

- **Neil Livingstone, PhD** - Dr. Livingstone is currently the Chairman and Chief Executive Officer of ExecutiveAction LLC. He was the founder and, until January, 2007, Chief Executive Officer of GlobalOptions Inc., which went public in 2005. He is also Lead Director of Erickson Air-Crane, a \$200 million helicopter company. Dr. Livingstone has noted expertise on national security, and is the author of nine books on terrorism. He has served on advisory panels to The Secretary of State, The Chief of Naval Operations, and The Pentagon. He has testified before Congress and delivered more than 500 major addresses in the U.S. and abroad, including recent speeches at The House of Commons and The United Nations. Dr. Livingstone serves on numerous advisory boards, including Supercom Inc., Digital Ally, the Africa Society, and No Greater Love. He was the Founder and Chairman of the Institute on Terrorism and Sub-national Conflict and served as President of Watergate South for more than seven years.
- **Bradford Billet, OBE CEM** - Mr. Billet is an executive with the City of New York, where his responsibilities include matters of international affairs, security and emergency management. He is also chairman of the Billet Group, a management consulting company. During the past 20 plus years, Mr. Billet has acquired extensive experience in International Affairs, Emergency Management, Security, Governmental and Business Management, Administration and Operational disciplines. He has held high-ranking positions in both the private and public sectors with budgets in excess of 180 million dollars. Mr. Billet has responded, coordinated and directed multi agency emergency operations, including the September 11th attacks and the 1993 bombing of the World Trade Center, 20 aviation accidents as well as numerous manmade and natural disasters, involving mass casualties and/or fatalities.
- **Dr. George Smith, MD** - Dr. Smith graduated from University of California Los Angeles (UCLA) Medical School with five years of specialty training in Pathology in 1965. He spent two years in the Public Health Service assigned to the Atomic Bomb Commission in Hiroshima, Japan. During this assignment, he examined surgical tissue from hospitals all over western Japan and from people who were exposed to radiation from the bombing. He rejoined the UCLA Pathology faculty in 1967 until retirement, in July of 1999. For six years he was Assistant Head of the Blood Bank and Associate Head of Hematopathology where he established a unique bone marrow service in the UCLA Medical Center, and continued to assist in these functions for over 30 years. Dr. Smith was appointed the Director of the UCLA Clinical Laboratories in 1975 and during this period he was also the Director of the Blood Bank, Director of the Medical Technologist Training Program and Chief of Clinical Pathology. Under his tutelage, the Blood Bank was greatly expanded by adding a Blood Donor Center, an apheresis center and new facilities that are all in use today. He initiated a designated donor program, a very active autologous donor program and designed a transfusion safety program.



Investment Summary

- **Strategic Alliances:** Today's revenues from collection, processing & storage are strategic alliances
- **Focused Acquisition Strategy:** Focused on acquiring licensing technology and R&D of therapies to provide value for the future.
- **China Expansion:** Move will allow a profitable traditional therapeutic business while we roll out stem cell based therapies underpinned by profitable pharmaceutical business with strong growth prospects.
- **Regulatory Arbitrage;** addressing the mismatch in regenerative medicine regulatory regimes
- **Vertically Integrated Platform;** partnering the stem cell leadership position of US with the delivery platform being installed in China, underpinned by balance sheet and P&L of Pharma operations
- **Largest Developing Healthcare Markets:** Positions in two of the world's leading healthcare markets by size and potential – US and China
- **China market** presents opportunity with latent domestic demand complemented by medical tourism flows
- **Untapped potential demand** for healthcare services in general in China, with healthcare expenditure at only US \$94 per capita per annum (4.6% of GDP) versus US \$6,719 (15.3% of GDP) in the US [Source: Who, 2006]



NeoStem®

Contact Information

Robin Smith, MD MBA
Chairman & CEO
Direct: (212) 584-4174
Email: rsmith@neostem.com

NeoStem, Inc.
420 Lexington Avenue
Suite 450
New York, NY 10170
Main: (212) 584-4180
Fax: (646) 514-7787
www.neostem.com
1.888.STEM BANK



